Evolus Inc (EOLS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $438.83M
Last updated: Nov 17, 2026 at 4:26 PM ET
Evolus Inc (EOLS) Statistics
Evolus (EOLS) has a market cap of $438.83M and an enterprise value of $554.03M. It earned -$31.11M on revenue of $325.47M over the last 12 months.
Total Valuation
Enterprise value is 26.25% above the market cap, as debt exceeds cash.
| Market Cap | $438.83M |
|---|---|
| Enterprise Value | $554.03M |
| Latest price (Nov 17, 2026) | $6.69 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 1.4x. Its year-end P/S ranged from 1.4x to 10.2x from 2019 to 2025.
| P/S Ratio | 1.4x |
|---|---|
| Forward P/S | 1.3x |
Price Statistics
The stock is down 7.34% over 52 weeks and trades 11.04% below its 50-day average.
| Beta (1Y) | 1.34 |
|---|---|
| 52-Week Change | -7.34% |
| 1-Month Change | -9.10% |
| 3-Month Change | -22.21% |
| 6-Month Change | +4.04% |
| 5-Year Change | -6.01% |
| Total Return (1Y) | -7.34% |
| Total Return (3Y CAGR) | -10.65% |
| Total Return (5Y CAGR) | +0.27% |
| Return vs SPY (1Y) | -16.40% |
| Max Drawdown (1Y) | -45.43% |
| Max Drawdown (3Y) | -77.47% |
| Sharpe Ratio (1Y) | -0.08 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $7.52 |
| 200-Day Average | $6.39 |
| 52-Week Range | $3.86 to $9.31 |
| RSI (14 Days) | 41.0 |
| Average Volume (20 Days) | 1.09M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.42x current liabilities.
| Current Ratio | 1.42x |
|---|---|
| Quick Ratio | 0.84x |
| Interest Coverage | -0.92x |
Returns and Efficiency
Return on invested capital is -12.69% over the last 12 months, against a 5-year average of -26.99%.
| Return on Assets (ROA) | -10.96% |
|---|---|
| Return on Invested Capital (ROIC) | -12.69% |
| Return on Capital Employed (ROCE) | -10.68% |
| ROA (5Y Average) | -27.43% |
| ROIC (5Y Average) | -26.99% |
| Asset Turnover | 1.29x |
| Inventory Turnover | 1.77x |
| Receivables Turnover | 5.31x |
| Cash Conversion Cycle | 57 days |
Scores
EOLS has an Altman Z-Score of -1.37, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.37 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $325.47M over the last 12 months is up 13.87% from the 12 months before.
| Revenue | $325.47M |
|---|---|
| Revenue Growth (YoY) | +13.87% |
| Gross Profit | $216.05M |
| Operating Income | -$15.60M |
| Pretax Income | -$30.34M |
| Net Income | -$31.11M |
| EBITDA | -$2.63M |
| EBIT | -$15.11M |
| Reported EPS (TTM) | -$0.29 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $41.70M |
|---|---|
| Total Debt | $156.90M |
| Net Debt | $115.20M |
| Net Debt Per Share | $1.74 |
| Working Capital | $59.36M |
| Shareholder Equity | -$37.81M |
| Tangible Book Value | -$105.75M |
| Total Assets | $283.82M |
| Total Liabilities | $321.64M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $5.59M of capital spending, operating cash flow left -$8.23M of free cash flow.
| Operating Cash Flow | -$2.65M |
|---|---|
| Capital Expenditures | $5.59M |
| Free Cash Flow | -$8.23M |
| FCF Per Share | -$0.12 |
| Depreciation and Amortization | $12.48M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -4.79%, against a 5-year average of -27.36%.
| Gross Margin | 66.38% |
|---|---|
| Operating Margin | -4.79% |
| Pretax Margin | -9.32% |
| Net Margin | -9.56% |
| EBITDA Margin | -0.81% |
| EBIT Margin | -4.64% |
| FCF Margin | -2.53% |
| Gross Margin (5Y Average) | 63.92% |
| Operating Margin (5Y Average) | -27.36% |
| Net Margin (5Y Average) | -32.77% |
Growth
Revenue grew 25.98% a year over 3 years.
| Revenue Growth (3Y CAGR) | +25.98% |
|---|---|
| Revenue Growth (5Y CAGR) | +39.36% |
Dividends and Yields
EOLS does not pay a dividend. Its free cash flow yield is -1.86%.
| FCF Yield | -1.86% |
|---|---|
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
Peer Position
Against 10 similar companies, EOLS has the 7th highest P/S.
P/S RatioPeer median 1.8x
ROICPeer median -3.84%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +15.45%
| P/S Ratio | 1.4x vs 1.8x median |
|---|---|
| ROIC | -12.69% vs -3.84% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.87% vs +15.45% median |
Analyst Forecast
Consensus estimates put revenue growth at 14.65% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +14.65% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About EOLS
What is EOLS's market cap?
Evolus has a market cap of $438.83M. Its enterprise value, which adds debt and subtracts cash, is $554.03M.
How many shares of EOLS are outstanding?
Evolus has 66.09M shares outstanding. The count is up 2.10% from a year earlier.
Does EOLS pay a dividend?
No. Evolus does not pay a dividend.
How much debt does EOLS have?
Evolus has $156.90M of total debt and $41.70M of cash and equivalents, a net debt position of $115.20M.
EOLS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors